Arcus Biosciences Insider Sale Sparks Market Shift, but Casdatifan’s Promise Shines Through
Arcus Biosciences insider sale, market volatility, and the clinical‑trial status of Casdatifan, a promising HIF‑2α inhibitor for solid tumours.
5 minutes to read